Madrigal Pharmaceuticals MDGL

Russell 2000Russell 2000

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    -$2.74 (-0.53%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Madrigal Pharmaceuticals (MDGL) Business Model and Operations Summary
    Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

    Key Insights

    Madrigal Pharmaceuticals (MDGL) Stock Information & Key Business Metrics

    • Market Cap

      $11.61 Billion

    • Average Daily Volume

      306,772 Shares

    • 52-Week Range

      $265.00-$615.00

    • Free Cash Flow

      -$161.63 Million

    • Total Outstanding Shares

      22.71 Million Shares

    • Free Float

      16.79 Million Shares (75.6% Outstanding)

    • CEO

      William J. Sibold

    • Total Employees

      528

    • Current Dividend

      No dividend

    • IPO Date

      February 6, 2007

    • Headquarters

      200 Barr Harbor Drive, Suite 400, West Conshohocken, PA, 19428

    Financial Highlights

    Madrigal Pharmaceuticals (MDGL) Key Financial Metrics

    Earnings Reports

    Expected vs. Actual Quarterly Earnings-Per-Share & Revenue

    Short Volume

    Daily short volume activity identifies short-term trading pressure and potential price volatility

    Short Interest

    Bi-monthly short interest levels can be used to gauge bearish market sentiment and short squeeze potential

    Revenue Breakdown

    Distribution of revenue across unique business segments & geographies

    Cash Flow Statement

    Income Statement

    Balance Sheet

    Historical Stock Splits

    If you bought 35 shares of MDGL before July 25, 2016, you'd have 1 share today

    Historical Dividends

    MDGL does not currently pay dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about MDGL from trusted financial sources

    Related Companies

    Publicly traded companies similar to Madrigal Pharmaceuticals (MDGL)
    Boost your savings and earn 3.95% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.

    Compete

    The Daily FinanchleSPY Prediction

    Explore

    Live Market OverviewS&P 500 SPYNasdaq 100 QQQRussell 2000 IWMUnusual Options ActivityPrediction Markets

    Research

    News ArticlesEarnings CalendarIPO Calendar & DirectoryAll Tickers

    Financhle

    Login / Sign UpPro SubscriptionAbout UsCareersTerms & ConditionsPrivacy & Cookies Info

    ⓒ 2026 Financhle LLC. All Rights Reserved.